Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment

Xiaohua Li¹
Dalin Song²
Sean X Leng³

¹Dalian Medical University, Dalian, ²Department of Geriatrics, Qingdao Municipal Hospital, Qingdao, People’s Republic of China; ³Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract: The aim of this paper is to provide a comprehensive review of the epidemiological evidence linking type 2 diabetes mellitus and its related conditions, including obesity, hyperinsulinemia, and metabolic syndrome, to Alzheimer’s disease (AD). Several mechanisms could help to explain this proposed link; however, our focus is on insulin resistance and deficiency. Studies have shown that insulin resistance and deficiency can interact with amyloid-β protein and tau protein phosphorylation, each leading to the onset and development of AD. Based on these epidemiological data and basic research, it was recently proposed that AD can be considered as “type 3 diabetes”. Special attention has been paid to determining whether antidiabetic agents might be effective in treating AD. There has been much research both experimental and clinical on this topic. We mainly discuss the clinical trials on insulin, metformin, thiazolidinediones, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors in the treatment of AD. Although the results of these trials seem to be contradictory, this approach is also full of promise. It is worth mentioning that the therapeutic effects of these drugs are influenced by the apolipoprotein E (APOE)-ε4 genotype. Patients without the APOE-ε4 allele showed better treatment effects than those with this allele.

Keywords: type 2 diabetes mellitus, Alzheimer’s disease, insulin

Introduction

Type 2 diabetes mellitus (T2DM) is currently extremely common due to the prevalence of obesity, as well as the aging of the population.¹ Prevention and treatment strategies for the classical macrovascular and microvascular complications of diabetes mellitus have significantly improved. Therefore, people are living longer with diabetes mellitus, which might lead to the emergence of new complications. Dementia is one example of these emerging new complications.² Compared with the general population, the increased risk of dementia is 50%–150% in people with T2DM.³–⁵ Prince et al⁶ predicted that people living with dementia worldwide would increase from 35.6 million in 2010 to 115.4 million in 2050. If current studies have correctly predicted the association between dementia and T2DM, then the future burden of dementia, eg, Alzheimer’s disease (AD) and vascular dementia, might be even greater than that estimated as the prevalence of diabetes mellitus continues to rise.⁷ AD is the most common form and cause of dementia, accounting for 60%–80% of all cases.⁸

Over the past three decades, numerous epidemiological studies have shown a clear association between T2DM and an increased risk of developing AD. In addition, T2DM-related conditions, including obesity,⁹ hyperinsulinemia,¹⁰ and metabolic syndrome, may also be risk factors for AD. The exact mechanisms with clinical relevance are unclear. Several mechanisms have been proposed, including insulin resistance and...
deficiency, impaired insulin receptor and impaired insulin growth factor (IGF) signaling, glucose toxicity, problems due to advanced glycation end products and their receptors, cerebrovascular injury, vascular inflammation, and others. In this review, we discuss insulin resistance and deficiency. Currently, the drugs available are able to slow worsening of symptoms for 6–12 months but are effective in only about half of the treated population. Also, no effective drugs are expected to be approved soon, given that several promising new agents have failed in Phase III clinical trials. Therefore, it is important to accurately define the role of T2DM in the development of AD for preventing and treating the disease. In this review, we discuss the clinical trials on antidiabetic agents, ie, insulin, metformin, thiazolidinediones, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase (DPP)-4 inhibitors, in the treatment of AD.

Alzheimer’s disease

Clinically, AD is manifested by progressive memory loss and a gradual decline in cognitive function, eventually leading to premature death of the individual, that occurs typically 3–9 years after diagnosis. The neuropathological features associated with the disease include the presence of extracellular senile plaques containing amyloid-β (Aβ) protein, neurofibrillary tangles that consist mainly of intracellular and abnormally phosphorylated tau protein, and a dramatic loss of neurons and synapses, especially in the hippocampus and cortex. Considering these pathological changes, the “amyloid cascade hypothesis” is certainly the most popular current view. This hypothesis proposes that accumulation of Aβ, as either a consequence of increased production or decreased removal of Aβ, instigates all other downstream AD-associated phenomena and ultimately the disease itself.

Despite the indistinguishable clinical symptoms of dementia, there are two different types of origin-based AD. In a small proportion (familial early-onset AD), the disease has a genetic origin and is caused by missense mutations in three genes, ie, Aβ protein precursor, presenilin-1, and presenilin-2. These genes affect less than 5% of cases of AD, that usually happen in middle age. The great majority of AD cases are sporadic in origin, with older age, being female, vascular disease, head trauma, family history of dementia, and genetic factors (eg, apolipoprotein E [APOE] ε4 allele) as the mainly immutable risk factors. Aside from these factors, there are several controllable risk factors. In a recent study, international experts reached an agreement that more than half of sporadic or late-onset AD cases were related to seven controllable risk factors, ie, depression, diabetes, smoking, and obesity in middle age, high blood pressure in midlife, lack of exercise, and a lower level of education.

T2DM and its related conditions

When considering the links between T2DM and AD, it is important to consider the natural history that leads to T2DM. There are two underlying mechanisms involved, ie, insulin resistance and inadequate insulin secretion from pancreatic β-cells. Initially, pancreatic β-cells increase insulin secretion in response to insulin resistance, causing hyperinsulinemia, and are able to effectively maintain glucose levels below the T2DM range. When β-cell function begins to decline, insulin production is inadequate to overcome insulin resistance, and blood glucose levels rise, resulting in prediabetes and T2DM. Being overweight or obese is the major reason for insulin resistance. This natural history is also part of the metabolic syndrome, which includes hypertension, dyslipidemia, and elevated systemic inflammation. From a mechanistic standpoint, it is difficult to discern whether the main mechanism linking T2DM to AD is glycemia, hypertension, insulin resistance, or factors specifically related to adipose tissue. Because they are related sequentially and often occur simultaneously, understanding this relationship is fundamental to the study of the role of adiposity, hyperinsulinemia, metabolic syndrome, and diabetes in AD.

Epidemiological studies linking T2DM, obesity, hyperinsulinemia, and metabolic syndrome to AD

In the 1990s, the Rotterdam Study, aiming to determine the influence of T2DM on the risk of dementia and AD, found that T2DM almost doubled the risk of dementia and AD. In a longitudinal study of 1,138 subjects, they explored the relationship between the aggregation of vascular risk factors (hypertension, heart disease, current smoking) and AD and showed that diabetes and smoking were the strongest risk factors and the risk of AD associated with diabetes was stronger than previously reported (relative risk 3.8), independent of other vascular conditions. So far, numerous prospective epidemiological studies have explored the relationship between diabetes and AD, and most have identified diabetes as a risk factor for AD (Table 1). Studies specifically assessing the incidence of dementia in people with diabetes mellitus, adjusting for glycemic control, microvascular complications, and comorbidity (eg, hypertension and stroke), have also demonstrated an increased risk; eight of 13 longitudinal population-based studies were reviewed and
Table 1 Summary of representative prospective epidemiological studies relating type 2 diabetes mellitus to Alzheimer's disease

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study site</th>
<th>Study name</th>
<th>Age at baseline (years)</th>
<th>Follow-up (years)/start–end year</th>
<th>Total population/with diabetes (n)</th>
<th>RR of all dementia/95% CI</th>
<th>RR of Alzheimer's disease/95% CI</th>
<th>RR of vascular dementia (n)/95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ott et al[11]</td>
<td>the Netherlands</td>
<td>The Rotterdam study</td>
<td>&gt;55</td>
<td>2.1 (1991–1994)</td>
<td>6,370/692</td>
<td>1.9 (1.3–2.8)</td>
<td>1.9 (1.2–3.1)</td>
<td>NR</td>
</tr>
<tr>
<td>Peila et al[14]</td>
<td>USA</td>
<td>The Honolulu-Asia Aging Study</td>
<td>&gt;65</td>
<td>2.9 (NR)</td>
<td>2,574/900</td>
<td>1.5 (1.0–2.2)</td>
<td>1.8 (1.1–2.9)</td>
<td>2.3 (1.1–5.0)</td>
</tr>
<tr>
<td>Honig et al[16]</td>
<td>USA</td>
<td>Washington Heights-Inwood Columbia Aging Project</td>
<td>&gt;65</td>
<td>7 (1991–1998)</td>
<td>1,766/NR</td>
<td>NR</td>
<td>1.6 (1.0–2.4)</td>
<td>NR</td>
</tr>
<tr>
<td>Arvanitakis et al[17]</td>
<td>USA</td>
<td>Religious Orders Study</td>
<td>&gt;55</td>
<td>5.5 (1994–2003)</td>
<td>824/127</td>
<td>NR</td>
<td>1.7 (1.1–2.5)</td>
<td>NR</td>
</tr>
<tr>
<td>Borenstein et al[18]</td>
<td>USA</td>
<td>Kame Project</td>
<td>&gt;65</td>
<td>9 (1992–2001)</td>
<td>1,859/NR</td>
<td>NR</td>
<td>3.3 (1.4–8.1)</td>
<td>NR</td>
</tr>
<tr>
<td>Hayden et al[19]</td>
<td>USA</td>
<td>The Cache County Study</td>
<td>&gt;65</td>
<td>3.2 (1995–1999)</td>
<td>3,264/322</td>
<td>NR</td>
<td>NA</td>
<td>3.3 (1.0–9.8)</td>
</tr>
<tr>
<td>Akomolafe et al[20]</td>
<td>USA</td>
<td>Framingham Study</td>
<td>70 mean</td>
<td>12.7 (1977–1990)</td>
<td>2,210/202</td>
<td>2.4 (1.0–5.9)</td>
<td>3.0 (1.1–8.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Irie et al[21]</td>
<td>USA</td>
<td>The Cardiovascular Health Study</td>
<td>NR</td>
<td>5.4 (1992–1999)</td>
<td>2,547/320</td>
<td>1.4 (1.0–2.0)</td>
<td>1.6 (1.0–2.7)</td>
<td>0.8 (0.3–2.1)</td>
</tr>
<tr>
<td>Raffaitin et al[22]</td>
<td>France</td>
<td>The Three-City study</td>
<td>&gt;65</td>
<td>4 (1999–2004)</td>
<td>7,087/539</td>
<td>1.6 (1.1–2.4)</td>
<td>NA</td>
<td>2.5 (1.2–5.7)</td>
</tr>
<tr>
<td>Xu et al[23]</td>
<td>Sweden</td>
<td>Kungsholmen project</td>
<td>&gt;75</td>
<td>9 (1988–1997)</td>
<td>1,248/75</td>
<td>1.5 (1.0–2.1)</td>
<td>1.3 (0.9–2.1)</td>
<td>2.6 (1.2–6.1)</td>
</tr>
<tr>
<td>Ohara et al[25]</td>
<td>Japan</td>
<td>The Hisayama Study</td>
<td>&gt;60</td>
<td>15 (1988–2003)</td>
<td>1,017/150</td>
<td>1.7 (1.2–2.5)</td>
<td>2.1 (1.2–3.6)</td>
<td>NR</td>
</tr>
<tr>
<td>Cheng et al[26]</td>
<td>USA</td>
<td>Columbia Aging Project</td>
<td>&gt;65</td>
<td>9 (1999–2007)</td>
<td>1,488/253</td>
<td>1.7 (1.4–2.9)</td>
<td>1.6 (1.0–2.6)</td>
<td>NR</td>
</tr>
<tr>
<td>Li et al[27]</td>
<td>People's Republic of China</td>
<td></td>
<td>&gt;55</td>
<td>5 (2004–2009)</td>
<td>837/136</td>
<td>NR</td>
<td>1.6 (1.0–2.6)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; RR, relative risk; NR, no report; NA, no association.
Many studies have explored the association between obesity and AD. Obesity, especially obesity in middle age, usually assessed by body mass index (BMI) or waist circumference, has a strong and independent association with an increased risk for AD. The Baltimore Longitudinal Study of Aging showed that the incidence of AD increased in men who gained weight between the ages of 30 and 45 years and in women with a BMI >30 at ages 30, 40, and 45 years. A meta-analysis reported an increased risk (95% CI 1.59–2.62) of AD with obesity (BMI ≥30), and people with the APOE-ε4 allele had a higher level of risk. The Honolulu-Asia Aging Study reported that groups with and without dementia showed no differences in weight from midlife to late life. The explanation for this difference may be ethnicity, ie, Asians may be more susceptible to the effects of obesity compared with Europeans. A meta-analysis of 16 papers found that many types of abnormal body weight in midlife, including underweight, overweight, and obesity, increase the risk of dementia.

The results of studies of late-life obesity with AD have been conflicting, and the following four conditions have been suggested: an increased risk, a reduced risk, no relationship, and a U-shaped relationship, with both high and low BMI related to an increased risk of AD. Higher BMI at ages 70, 75, and 79 years predicts a higher dementia risk; however, an analysis of the Cardiovascular Health Study of subjects ≥65 years of age found a 40% decreased risk with BMI >30 compared with subjects of normal weight. Whitmer reported a decreased risk of dementia with increasing BMI in subjects ≥76 years of age, but a U-shaped association in subjects <76 years of age. They also found that a higher waist circumference is related to a higher AD risk in the younger elderly, but not in the oldest population. The causes for this paradox remain unclear. There may be weight decreases with aging and frailty. It has been suggested that changes in body composition with age make BMI a poor measure of obesity in the elderly; survival bias related to high obesity may be an important factor, and midlife studies had a much longer period of follow-up prior to diagnosis of dementia. The average length of follow-up for the late-life studies was 7.13 years, which would include the prodromal phase of AD in particular. Further data are required from studies with longer durations of follow-up in late life, and more suitable weight indicators are needed for the elderly.

**Hyperinsulinemia**

Recent attention has turned to the question of whether hyperinsulinemia may directly increase the risk of cognitive decline. Two longitudinal studies, one in elderly Japanese Americans in Hawaii and another in persons aged 65 years...
and older from northern Manhattan, found that the risk of incident AD was higher in persons with hyperinsulinemia. These studies also found that the risk of AD related to hyperinsulinemia was higher among persons with the APOE-e4 allele. Another study found that higher c-peptide levels, a measure of insulin secretion, may be related to worse cognition, even among those without diabetes. The Nurses’ Health Study found that “young-old” women (mean age 64 years) without diabetes but with higher c-peptide levels showed cognitive decline approximately 10 years later. In the Physicians’ Health Study II, older men aged 60–92 (mean 71.3) years showed similar results. Therefore, hyperinsulinemia may be the reason for T2DM being associated with an increased risk for AD.

Metabolic syndrome
Metabolic syndrome, first described about 40 years ago, has a cluster of risk factors including abdominal obesity, hypertension, lipid abnormalities, and impaired metabolism of glucose and insulin. Studies addressing the association between metabolic syndrome and AD are limited and the results are mixed. One study in 2,632 elderly black and white people found that the metabolic syndrome measured using National Cholesterol Education Program guidelines was associated with a higher risk of cognitive decline, particularly among those with high levels of inflammatory markers. A population-based study of 980 elderly subjects aged 69–78 years found that the metabolic syndrome is significantly associated with AD. However, this suggested association between metabolic syndrome and AD was not confirmed by four large, longitudinal, population-based studies, including the Honolulu-Asia Aging Study, the Three-City Study, the Italian Longitudinal Aging Study, and a multiethnic elderly cohort in the USA. However, the prevalence of metabolic syndrome depends on the studied population and the definition, except for the most commonly used definition, ie, the Third Adults Treatment Panel of the National Cholesterol Education Program criteria. At least two other more recent sets of clinical criteria were also presented, ie, the National Heart, Lung and Blood Institute/American Heart Association criteria and the International Diabetes Federation criteria. It is still unclear if one or two separate components of metabolic syndrome can drive the relationship with cognitive decline, or whether the individual components are additive or interact in some way. Individual components of the metabolic syndrome should not be evaluated in isolation, and careful methodological approaches are needed to understand the timing and non-linear relationships between these components over time.

Insulin resistance and deficiency: potential mechanisms linking T2DM and its related conditions to AD
A large number of studies have shown that insulin resistance and deficiency, a marker of T2DM, play an important role in AD pathology. The first molecular clue as to how the brain might become insulin-resistant in AD came from studies demonstrating that Aβ oligomers bind to hippocampal neurons and trigger the removal of dendritic insulin receptor substrates (IRs) from the plasma membrane, which was subsequently demonstrated in AD brains. Lower levels and sensitivity of insulin, IGF, and IRs were observed in AD neuropathology. Greatly increased biomarkers of peripheral insulin resistance in the hippocampus of non-diabetic AD patients further implicated insulin resistance in AD. In T2DM, tumor necrosis factor (TNF)-α signaling activates c-Jun N-terminal kinase, resulting in IRs-1 serine phosphorylation and peripheral insulin resistance. Similarly, Aβ oligomers cause abnormal activation of the TNF-α/c-Jun N-terminal kinase pathway and inhibition of IRs-1 in cultured hippocampal neurons. Recently, it was even proposed that AD can be an “insulin-resistant brain state” or even a “type 3 diabetes”. Insulin was found to modulate Aβ protein precursor expression and processing both in vivo and in vitro. Insulin and IGF-1 inhibited Aβ production through Akt-mediated phosphorylation/inactivation of glycogen synthase kinase-3β and prevented abnormal intracellular accumulation of Aβ by increasing its extracellular secretion in the brain and accelerating its trafficking from the Golgi and trans-Golgi network to the plasma membrane. Insulin and IGF-1 also prevented accumulation of Aβ by promoting the transport of Aβ-binding carrier proteins, including transthyretin and albumin, into the brain. Devi et al demonstrated that streptozotocin-induced insulin-deficient diabetes accelerates Aβ accumulation via the translational upregulation of the β-secretase enzyme, BACE1, and its substrate, amyloid precursor protein, in a transgenic mouse model of AD. Another potential mechanism could be the interference of insulin with extracellular proteolytic Aβ degradation occurs via the insulin-degrading enzyme, a metalloprotease that also catabolizes insulin and IGF-1. Under insulin resistance conditions, insulin may competitively inhibit the insulin-degrading enzyme, thus impairing degradation of Aβ, increasing its neurotoxicity and promoting AD. Besides Aβ, insulin resistance and deficiency also increases tau protein phosphorylation through activation of glycogen synthase kinase-3β.

Considering the above, neurons in the T2DM brain could be more vulnerable to the toxicity of Aβ due to insulin deficiency.
resistance and deficiency. Conversely, insulin resistance and deficiency could lead to increased production of Aβ and Aβ-induced oxidative damage at the mitochondria. Therefore, the current hypothesis regarding insulin resistance and deficiency may represent a critical contributing factor in the acceleration of Aβ production during the progression of sporadic AD (Figures 1 and 2), and thus insulin resistance and deficiency may be an important therapeutic target in patients with AD.

**Implications for treatment of AD with or without T2DM**
Given the role of insulin resistance and deficiency in the pathogenesis of AD, it could be possible that a drug currently approved for T2DM may also be useful for AD (Figure 3). We now summarize some of the relevant clinical trials.

**Intranasal insulin**
Insulin has also been studied in cognitively impaired patients, because intranasal administration can quickly deliver insulin to the central nervous system across olfactory and trigeminal perivascular channels and axonal pathways, and there are fewer potential side effects, such as hypoglycemia, when compared with intravenous insulin infusions. Thus, intranasal delivery of insulin is a viable long-term therapy for AD. A 2008 study reported that intranasal insulin (20 IU, twice a day) for 21 days improved story recall, attention, and caregiver-rated functional status in cognitively impaired subjects or individuals with AD. In another study, 40 individuals with AD and 64 with mild cognitive impairment received either placebo, 20 IU of insulin, or 40 IU of insulin administered via nasal spray over the course of 4 months. The between-subject comparison showed that intranasal insulin improved delayed memory and cognitive function. Based on positron emission tomography findings, the authors also provided evidence that both doses of insulin had a higher 18F fluorodeoxyglucose uptake in the parietotemporal, frontal, precuneus, and cuneus regions of the central nervous system following administration of intranasal insulin compared with placebo, linking the enhancement in function of those brain areas. Given what is known about AD and diabetes, it is not surprising that intranasal insulin could have different effects depending on the APOE-ε4 genotype. In a study by Reger et al the participants were further subdivided based on APOE-ε4 genotype (APOE-ε4 negative or positive allele), and cognitive function was measured 45 minutes after administration of intranasal treatment. Participants with the APOE-ε4 negative allele displayed significant cognitive improvement on the 20 IU and 40 IU doses when compared with the placebo group and the APOE-ε4 positive group, and patients in the APOE-ε4 negative group taking 40 IU of insulin performed better than patients in the other groups. In the APOE-ε4 positive group, cognitive function (working and verbal memory) was reduced with treatment. Currently, the sample size of clinical trials exploring insulin administration in AD patients seems to be relatively low, with a relatively short treatment period. Therefore, longer trials are needed, as well as APOE-ε4 allele related differences in insulin metabolism.

**Metformin**
Metformin is an orally active biguanide that lowers blood glucose levels by suppressing hepatic glucose output, increasing insulin-mediated glucose disposal, increasing intestinal glucose use, and decreasing fatty acid oxidation. It also reduces insulin levels, inflammation and thrombosis, and the risks of metabolic syndrome and diabetes in persons without diabetes. Long-term use of metformin is also associated with a lower risk of certain cancers. While the mechanisms of

![Figure 1](https://www.dovepress.com/clinical-interventions-in-aging-downloaded-from-httpswww.dovepress.comby54.70.40.11on22-Dec-2018) Overview of the role of insulin resistance and insulin deficiency in the pathology of Alzheimer’s disease.

**Abbreviations:** BACE1, β-site amyloidogenic cleavage of precursor protein-cleaving enzyme 1; GSK-3β, glycogen synthase kinase-3β; IDE, insulin-degrading enzyme; IRs, insulin receptor substrates; TNF, tumor necrosis factor; JNK, c-Jun N-terminal kinase; APP, amyloid precursor protein; Aβ, amyloid-β; IGF, insulin growth factor.
Clinical Interventions in Aging downloaded from https://www.dovepress.com/ by 54.70.40.11 on 22-Dec-2018
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Antidiabetic agents in Alzheimer's disease

Figure 2 The underlying link between Alzheimer’s disease and type 2 diabetes mellitus.
Notes: Insulin resistance reduces the degradation of Aβ by IDE, and makes the combination of insulin and insulin receptor impaired. Under normal conditions, the insulin signaling pathway can inhibit Aβ production and tau protein phosphorylation through inhibiting the translation of β-site amyloidogenic cleavage of BACE1 and its substrate APP, and inhibiting phosphorylation of GSK-3β. In addition, the insulin signaling pathway prevents abnormal intracellular accumulation of Aβ by accelerating its trafficking from the Golgi and trans-Golgi network to the plasma membrane and increasing its extracellular secretion. However, insulin resistance and deficiency make insulin signal conduction abnormal, leading to increased production of Aβ in the brain with Alzheimer’s disease. Increased Aβ monomers gather into oligomers. Aβ oligomers cause abnormal activation of the TNF-α/JNK pathway, resulting in insulin resistance. Further, insulin and IGF-1 deficiency promote Aβ accumulation by decreasing the Aβ-binding carrier proteins. Aβ oligomers can also induce oxidative damage of the mitochondria.
Abbreviations: APP, amyloid precursor protein; Aβ, amyloid-β; IDE, insulin-degrading enzyme; BACE1, β-site amyloidogenic cleavage of precursor protein-cleaving enzyme 1; GSK-3β, glycogen synthase kinase-3β; IRs, insulin receptor substrates; TNF-α, tumor necrosis factor alpha; JNK, c-Jun N-terminal kinase; IGF-1, insulin-like growth factor 1.

Figure 3 Possible mechanisms of antidiabetic drugs in the treatment of AD.
Notes: The red line represents inhibition. The green line represents promotion.
Abbreviations: AD, Alzheimer’s disease; DPP-4, dipeptidyl peptidase-4; TZDs, thiazolidinediones; GLP-1R, glucagon-like peptide-1 receptor.
action are not completely understood for metformin, studies have shown that patients with T2DM and AD, and receiving antidiabetic drugs including metformin, have a lower rate of cognitive impairment than in untreated patients. This result suggests that diabetic medication might somehow affect neuronal networks in the brain, leading to functional preservation or benefit in AD patients. In a large epidemiological study comparing individuals with T2DM, either taking antidiabetic drugs or not, metformin and sulfonylureas decreased the risk of dementia by 35% over 8 years in patients with T2DM. Notably, another large epidemiological trial, based on the UK-based General Practice Research Database, including 7,086 individuals aged 65 years and older with an incident diagnosis of AD and the same number of matched controls without dementia, showed that patients with T2DM who were long-term users of metformin had a slightly higher risk of AD than those who did not receive the drug. The conflicting results of these studies point to more research being needed.

**Thiazolidinediones**

Thiazolidinediones are peroxisome proliferator-activated receptor-γ (PPARγ) agonists and potent insulin sensitizers. Their mechanism involves stimulation of the action of PPARγ in response to changes in insulin, thereby triggering a drop in serum glucose. The best characterized PPARγ agonists are pioglitazone and rosiglitazone. Thiazolidinediones also have potent anti-inflammatory properties. Given the role of insulin resistance and inflammation in the pathogenesis of AD, these agents are being studied as a potential treatment for AD. One small study showed that persons receiving rosiglitazone 4 mg daily had improved memory and selective attention. In a larger trial, more than 500 patients with mild to moderate AD were randomized to 6 months of treatment with placebo or rosiglitazone 2, 4, or 8 mg, resulting in significant improvement on the Alzheimer's Disease Assessment Scale-cognitive subscale in APOE-ε4-negative patients on 8 mg rosiglitazone, while persons with the APOE-ε4 allele showed no benefit. However, a Phase III trial of rosiglitazone (NCT00428090) in mild to moderate AD found no benefit. Pioglitazone and rosiglitazone seem to have similar results. Researchers in one study reported improvement of cognition with pioglitazone in patients with both T2DM and AD, whereas another study showed no effect. The major limitation of thiazolidinediones in the prevention of dementia is the side effects of edema and congestive heart failure. In the interests of safety, the USA and Europe have either partially or completely restricted the use of rosiglitazone for treatment of T2DM. Therefore, solving these side effect issues is very important for the future application of thiazolidinediones.

**GLP-1R agonists and DPP-IV inhibitors**

GLP-1 is a gut-derived incretin hormone that enhances glucose-stimulated insulin secretion and suppresses glucagon secretion. GLP-1 is rapidly degraded by DPP-4; however, administration of specific DPP-4 inhibitors can increase the half-life of endogenous GLP-1 and hence prolong the activation of GLP-1R in different cell types. Currently, GLP-1R agonists and DPP-4 inhibitors are routinely used to treat T2DM. In agreement with the proposed role of insulin signaling declining with the development of AD, GLP-1R agonists are an attractive option because they activate pathways common to bypassing IRs and boost insulin-related signaling pathways through G protein-dependent signaling. In fact, animal studies have revealed that GLP-1R plays an important role in the control of synaptic plasticity and in some forms of memory formation. Exendin-4 and liraglutide, two types of GLP-1R agonists, also restored impaired insulin signaling, exerting neuroprotective effects on neurons and synapses, improving cognition, and decreasing Aβ accumulation in the brain in a transgenic mouse model of AD. As recently suggested, an agent that chronically decreases Aβ levels should be beneficial in APOE-ε4 allele carriers. If the beneficial effect of GLP-1R agonists is found to translate to primates, APOE-ε4 allele carriers may possibly benefit from the use of GLP-1R agonists. Similarly, the DPP-4 inhibitors, sitagliptin and vildagliptin, have been found to have beneficial effects on learning and memory in animal models. Unfortunately, no relevant clinical data are available. We are awaiting the results of two clinical trials, ie, a study of exendin-4 in 230 patients with mild cognitive impairment/early-stage AD (NCT01255163) and a large-scale Phase II clinical trial assessing the safety and efficacy of liraglutide in 206 patients with mild cognitive impairment (NCT01843075).

**Summary**

T2DM and AD have traditionally been treated as independent disorders. With extensive and in-depth research on T2DM and AD, epidemiological associations and some common pathophysiological mechanisms have been found. If demonstrated to be true, common pharmacotherapy should be effective, and clinical trials testing the effectiveness of antidiabetic drugs in AD patients should be initiated. The results...
will not only be important for the treatment of AD patients, but will also be key to understanding the connection between these serious but seemingly unrelated disorders.

Acknowledgment

We thank LetPub (www.letpub.com) for its assistance with English language during preparation of this manuscript.

Disclosure

The author reports no conflicts of interest in this work.

References


